ERIC POWELL, M.D.
Medical Practice at Science Center Dr, San Diego, CA
License number
California 01060833A
Category
Medical Practice
Type
Anatomic Pathology
Address
Address
2
10777 Science Center Dr, San Diego, CA 92121
100 Sportfisher Dr UNIT 301, Oceanside, CA 92054
100 Sportfisher Dr UNIT 301, Oceanside, CA 92054
Phone
(858) 622-7572
(317) 908-8807
(317) 908-8807
Professional information
Varsity Line Backer Coach At Mira Mesa High School
Position:
Varsity Line Backer Coach at Mira Mesa High School
Location:
Greater San Diego Area
Industry:
Education Management
Work:
Mira Mesa High School
-
Varsity Line Backer Coach
Method For Selection Of Chemotherapeutic Agents For Adenocarcinoma Cancer
US Patent:
2013011, May 9, 2013
Filed:
Aug 2, 2012
Appl. No.:
13/565380
Inventors:
Jeffrey Dean Isaacson - Superior CO, US
Mical Raponi - San Francisco CA, US
James Ranger-Moore - Tucson AZ, US
Eric L. Powell - Oceanside CA, US
Mical Raponi - San Francisco CA, US
James Ranger-Moore - Tucson AZ, US
Eric L. Powell - Oceanside CA, US
Assignee:
VENTANA MEDICAL SYSTEMS, INC. - Tucson AZ
CLOVIS ONCOLOGY, INC. - Boulder CO
CLOVIS ONCOLOGY, INC. - Boulder CO
International Classification:
A61K 31/7068, C07H 19/00
US Classification:
514 49, 435 723, 536 285
Abstract:
The subject invention relates to determining the presence and level of hENT1 expression in tumor tissue that is appropriate for gemcitabine therapy, and more importantly, the level of hENT1 expression that signifies that treatment with a gemcitabine derivative is a more appropriate strategy.
Method For Selection Of Chemotherapeutic Agents For Adenocarcinoma Cancer
US Patent:
2013011, May 9, 2013
Filed:
Aug 2, 2012
Appl. No.:
13/565283
Inventors:
Jeffrey Dean Isaacson - Superior CO, US
Mical Raponi - San Francisco CA, US
James Ranger-Moore - Tucson AZ, US
Eric L. Powell - Oceanside CA, US
Mical Raponi - San Francisco CA, US
James Ranger-Moore - Tucson AZ, US
Eric L. Powell - Oceanside CA, US
Assignee:
VENTANA MEDICAL SYSTEMS, INC. - Tucson AZ
CLOVIS ONCOLOGY, INC. - Boulder CO
CLOVIS ONCOLOGY, INC. - Boulder CO
International Classification:
G01N 33/68
US Classification:
435 723
Abstract:
The subject invention relates to determining the presence and level of hENT1 expression in tumor tissue that is appropriate for gemcitabine therapy, and more importantly, the level of hENT1 expression that signifies that treatment with a gemcitabine derivative is a more appropriate strategy.